
Morepen Labs shares gained 2.37% to trade at ₹94.43 on November 8, 2026, building on the previous session's 5% surge that snapped an eight-session losing streak. The stock had earlier announced its first prescription generic product launch, demonstrating sustained investor confidence in the company's strategic shift into the US prescription generic market. The positive momentum reflects market appreciation for Morepen's expansion into finished-dosage medicines and distribution capabilities in the regulated US market.
Indian pharmaceutical and healthcare company Morepen Laboratories announced the launch of its first prescription generic product, Desloratadine Tablets USP, 5 mg, in the US market. According to regulatory filings, the company is introducing the product in 100-count and 500-count packs through Morepen Bio Inc., its wholly owned US subsidiary. While Morepen has supplied Desloratadine active pharmaceutical ingredient (API) to the US market for several years, this launch extends the company's presence further up the pharmaceutical value chain into finished-dosage medicines and distribution in the US. The prescription generics expansion follows Morepen's earlier U.S. OTC product introductions, demonstrating the company's growing capabilities in formulation development, analytical science and regulatory filings.
Morepen Laboratories reported robust financial metrics with quarter-on-quarter revenue growth of 31.27%, marking the highest growth in the last three years according to consolidated financials. However, the company experienced a revenue contraction of 0.16% for the first time in three years, indicating some seasonal or market-specific challenges. The company maintains efficient cost management with less than 1% of operating revenues spent on interest expenses and 12.89% allocated to employee costs in the year ending March 31, 2026. With a market capitalization of ₹5,054.87 crore and trading at a PE ratio of 27.44 and PB ratio of 4.15, Morepen maintains its position within the top 64 companies by market cap in the pharmaceuticals sector.
Morepen Laboratories Managing Director Sanjay Suri stated that the company's long-standing API relationships in regulated markets provide a strong foundation for growth. As reported by CNBC TV18, Suri emphasized that alongside their expanding CDMO business, they are selectively extending their capabilities into finished-dosage development and US distribution. This strategy reflects their goal to build a more integrated, R&D-led pharmaceutical business with sustainable, long-term growth opportunities. The initiative demonstrates Morepen's growing capabilities in formulation development, analytical science and regulatory filings, marking a significant step in its pharmaceutical business evolution.
The launch follows Morepen's earlier introduction of over-the-counter (OTC) products in the US market. According to regulatory filings, the company has also submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitagliptin Phosphate Tablets in strengths of 25 mg, 50 mg and 100 mg. An ANDA represents the US FDA's regulatory pathway for approving generic drugs, allowing manufacturers to market generic versions by demonstrating bioequivalence to the original drug without repeating full clinical trials. The application is currently under regulatory review, with Morepen planning to pursue additional US prescription generic filings and distribution opportunities where its established API and pharmaceutical research and development capabilities provide a competitive advantage.
The company may also evaluate opportunities in high-potency APIs (HPAPIs) and oncology, subject to development feasibility, regulatory requirements and market conditions. As reported by CNBC TV18, this strategic expansion represents Morepen's commitment to building a comprehensive pharmaceutical business with diversified revenue streams across different therapeutic areas and market segments. The move into prescription generics follows the company's earlier launch of over-the-counter products in the US market, marking a significant step in its pharmaceutical business evolution.